DUBLIN–(BUSINESS WIRE)–The “Respiratory Diseases Drugs Global Market Report 2019” report has been added to ResearchAndMarkets.com’s offering.
Global Respiratory Diseases Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global respiratory diseases drugs market.
Where is the largest and fastest growing market for the respiratory diseases drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Respiratory Diseases Drugs market global report answers all these questions and many more.
The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold.
North America was the largest region in the global respiratory diseases drugs market, accounting for 42% of the market in 2018. Western Europe was the second largest region accounting for 27% of the global respiratory diseases drugs market. Africa was the smallest region in the global respiratory diseases drugs market.
The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products.
For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.
Key Topics Covered:
1. Executive Summary
2. Report Structure
3. Respiratory Diseases Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Respiratory Diseases Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Respiratory Diseases Drugs Market Supply Chain
5.1. Supply Chain
5.3. End Customers
6. Respiratory Diseases Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Respiratory Diseases Drugs Market Trends And Strategies
8. Respiratory Diseases Drugs Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, Value ($ Billion)
8.2.1. Drivers Of The Market
8.2.2. Restraints On The Market
8.3. Forecast Market Growth, Value ($ Billion)
8.3.1. Drivers Of The Market
8.3.2. Restraints On The Market
9. Respiratory Diseases Drugs Market Regional Analysis
9.1. Global Respiratory Diseases Drugs Market, 2018, By Region, Value ($ Billion)
9.2. Global Respiratory Diseases Drugs Market, 2014 – 2022, Historic And Forecast, By Region
9.3. Global Respiratory Diseases Drugs Market, Growth And Market Share Comparison, By Region
10. Respiratory Diseases Drugs Market Segmentation
10.1. Global Respiratory Diseases Drugs Market, Segmentation By Type, 2014 – 2022, Value ($ Billion)
10.1.1. Anti-Asthmatics And COPD Drugs
10.1.2. Cough And Cold Preparations
11. Respiratory Diseases Drugs Market Metrics
11.1. Respiratory Diseases Drugs Market Size, Percentage Of GDP, 2014 – 2022, Global
11.2. Per Capita Average Respiratory Diseases Drugs Market Expenditure, 2014 – 2022, Global
- GlaxosmithKline Plc
- AstraZeneca Plc
- Merck & Co
- Novartis AG
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/r/dn5240
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs